Estrogen Steroids Tazarotene for Treatment of Psoriasis CAS 118292-40-3

1.Basic Info.

CAS NO.:  118292-40-3 

Assay: 98%

Molecular Formula:C21H21NO2S 

Molecular Weight: 351.46 

Packing:25kg/drum

Appearance: Class white or light yellow solid

Usage: For the treatment of psoriasis, acne, and for unusual diseases keratosis, follicular disease, skin cancer, precancerous lesions

HS CODE:2937290090

Reference FOB Price:$1/g

MOQ:1kg

Specification:ISO9001,USP,BP,GMP

Trade Mark:CQSP

Port:Shenzhen/Shanghai,China

Production Capacity:5000kg/month

2.Description:

Tazarotene (marketed as Tazorac, Avage, Zorac, and Fabior) is a third-generation prescription topical retinoid sold as a cream, gel, or foam. Tazarotene is a member of the acetylenic class of retinoids. This medication is approved for treatment of psoriasis, acne, and sun damaged skin (photodamage). It is commonly sold in two concentrations: 0.05% and 0.1%.

3.Application:

Tazarotene is rated pregnancy category X, and should not be used by pregnant women.

"There is limited evidence that tazarotene and isotretinoin benefit patients with moderate photodamage on the face: both are associated with skin irritation and erythema." 

In addition to tretinoin, which has been associated with greater skin improvements with high concentrations, tazarotene and isotretinoin creams are also found to be effective for photodamage, but at the expense of skin irritation. More evidence is needed before any recommendations can be made on oral or topical polysaccharides or hydroxy acids. Evidence from one trial suggests that the effectiveness of 0.05% tretinoin, is equivalent to the effects of 0.05% and 0.1% tazarotene. However for acne vulgaris, several recent double blind studies have shown consistently superior efficacy for tazarotene and roughly equal tolerability for both treatments.

"Specifically, tazarotene reduced the number of noninflammatory and inflammatory lesions at 4, 8, and 12 weeks -- all timepoints examined during treatment. Although the reduction of inflammatory lesions compared with tretinoin did not achieve statistical significance, the reduction of open comedones at 12 weeks was 65% for tazarotene vs 44% for tretinoin (P = .034). Tazarotene also proved superior in the reduction of noninflammatory lesions at 12 weeks (55% vs 42% for tretinoin, P = .042)."